Trial Profile
Phase II trial of durvalumab plus tremelimumab in combination with targeted therapies [AZD-5069] as a second-line treatment in patients with pancreatic ductal adenocarcinoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2015
Price :
$35
*
At a glance
- Drugs AZD 5069 (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 03 Aug 2015 Status changed from not stated to planning.
- 03 Aug 2015 New trial record